Scarica l'app Stockscreener
45.00
4.87%
2.09
Dopo l'orario di chiusura:
45.50
0.50
+1.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GPCR Giù?
Forum
Previsione
Structure Therapeutics Inc Adr Borsa (GPCR) Ultime notizie
(GPCR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock? - TradingView
Why Structure Therapeutics’ Hot Obesity Stock Is Suddenly Sinking - TipRanks
H.C. Wainwright cuts Structure Therapeutics stock price target to $70 By Investing.com - Investing.com Canada
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs? - TradingView
Why Structure Therapeutics Shares Are Suddenly Sinking - TipRanks
Structure Therapeutics Maintained at Buy as Analyst Highlights Best-in-Class Oral GLP-1 Profile and Keeps $145 Price Target Unchanged - TipRanks
Why Structure Therapeutics Stock Is Sliding Today - TipRanks
Zevra Therapeutics (NASDAQ: ZVRA) vote keeps classified board structure - Stock Titan
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity - The Manila Times
Oral obesity drug helped people lose up to 16% body weight in trial - Stock Titan
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s? - TradingView
LLY Rises 14% in a Month: Should You Hold as Obesity Growth Continues? - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why Structure Therapeutics Stock Is Surging Higher - TipRanks
Structure Therapeutics IncADR (GPCR) News, Articles, Events & Latest Updates - Stocktwits
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), AngioDynamics (ANGO) - The Globe and Mail
LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst? - TradingView
Analysts Offer Insights on Healthcare Companies: Agilent (A), Apogee Therapeutics (APGE) and Pfizer (PFE) - The Globe and Mail
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million - AOL.com
Hear Structure Therapeutics at Jefferies and Goldman Sachs healthcare talks - Stock Titan
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth? - TradingView
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position - AOL.com
Why (GPCR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Why Structure Therapeutics Shares Are Sinking Today - TipRanks
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and Protara Therapeutics (TARA) - The Globe and Mail
Monashee Reduces Stake in Structure Therapeutics Amid Competitive Landscape - Intellectia AI
Monashee Scales Back Its Bet on Structure Therapeutics - Yahoo Finance
HighVista Strategies Sells 69,092 Shares of Structure Therapeutics in Q1 2026News and Statistics - IndexBox
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million - The Globe and Mail
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million - The Motley Fool
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Journey Medical Corp (DERM) - The Globe and Mail
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure? - TradingView
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail
Understanding Momentum Shifts in (GPCR) - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Siemens Healthineers AG (OtherSEMHF) and BioNTech SE (BNTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Cantor Fitzgerald - The Globe and Mail
NVO Rallies 21% in a Month: How Should Investors Play the Stock? - TradingView
Brokers Offer Predictions for GPCR Q1 Earnings - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
GPCR Structure posts massive EPS miss as losses widen; stock barely flinches, down 0.13%.Product Revenue - Newser
Structure Therapeutics ADA Data Could Reframe Oral Obesity And Diabetes Prospects - Sahm
Structure Therapeutics Reports 16% Weight Loss With Oral GLP-1RA Aleniglipron in Phase 2, Prepares for Phase 3 Obesity Trial and ADA 2026 Data Presentations - Minichart
Analysts’ Top Healthcare Picks: Addus Homecare (ADUS), Aardvark Therapeutics, Inc. (AARD) - The Globe and Mail
Structure Therapeutics Expands ATM Capacity, Advances Obesity Program - TipRanks
Structure Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Structure Therapeutics (NASDAQ: GPCR) funds obesity drug push with $1.46B cash - Stock Titan
Obesity drug gains momentum as Structure (NASDAQ: GPCR) eyes Phase 3, boosts ATM - Stock Titan
Obesity pill developer posts 16.3% weight loss, targets Phase 3 - Stock Titan
GPCR (NASDAQ: GPCR) expands ATM program to $400M capacity - Stock Titan
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Evolus (EOLS) - The Globe and Mail
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits? - TradingView
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Alignment Healthcare (ALHC) - The Globe and Mail
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock? - TradingView
Structure Therapeutics (GPCR) Is Down 7.2% After Strong Phase 2 Oral GLP‑1 Obesity Data – Has The Bull Case Changed? - Sahm
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):